| Literature DB >> 30426211 |
Yuan Xiong1, Qipeng Wu2, Bobin Mi1, Wu Zhou1, Yi Liu1, Jing Liu1, Hang Xue1, Liangcong Hu1, Adriana C Panayi3, Guohui Liu4.
Abstract
BACKGROUND: Corticosteroid (CS) injections have been proven to be effective in ameliorating symptoms of plantar fasciitis. Shock-wave (SW) therapy is another common treatment of plantar fasciitis, and several meta-analyses have documented its advantages when compared to placebo treatment. Despite this, few studies have focused on comparing the use of CS and SW in the treatment of plantar fasciitis. The purpose of this meta-analysis is to assess whether SW is superior to CS in managing plantar fasciitis, both in terms of ameliorating pain as well as improving functionality.Entities:
Keywords: Corticosteroid; Intra-articular; Plantar fasciitis; Shock-wave
Mesh:
Substances:
Year: 2018 PMID: 30426211 PMCID: PMC6420882 DOI: 10.1007/s00402-018-3071-1
Source DB: PubMed Journal: Arch Orthop Trauma Surg ISSN: 0936-8051 Impact factor: 3.067
Fig. 1Flow chart outlining the process of study identification, inclusion and exclusion
Characteristics of included studies
| Study | Year | Country | Patients ( | Age (Y) | Average disease duration, month (week) | PF thickness (mm) | Study design | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SW | CS | SW | CS | SW | CS | SW | CS | ||||
| Lai | 2018 | Taiwan, China | 47 | 50 | 54.53 ± 8.62 | 54.58 ± 8.63 | 7.94 ± 2.92 | 8.06 ± 2.87 | 0.37 ± 0.07 | 0.38 ± 0.06 | RCT |
| Sehriban | 2017 | Turkey | 36 | 36 | 50.22 ± 8.29 | 47.86 ± 7.90 | 8 | 9 | 4.75 | 4.7 | RCT |
| Mark | 2005 | Australia | 61 | 64 | 38.6 | 39.9 | 12.7 | 14.6 | NC | NC | RCT |
| Nayera | 2012 | Egypt | 30 | 30 | 34.27 ± 7.19 | 34.23 ± 6.67 | NC | NC | 5.94 ± 0.54 | 5.96 ± 0.46 | RCT |
| Istemi | 2010 | Turkey | 27 | 33 | 42.9 ± 7.08 | 44.7 ± 9.20 | 37.7 ± 8.6 | 39.4 ± 10.2 | NC | NC | RCT |
| Fariba | 2016 | Iran | 20 | 20 | 41.45 ± 8.05 | 42.85 ± 8.62 | 8.5 ± 4.53 | 10.4 ± 5.53 | NC | NC | RCT |
Characteristics of the six trials selected showing general information
| Study | Year | Treatment cycle | Treatment schedule | Assessment methods | Adverse event | Follow-up, month | |
|---|---|---|---|---|---|---|---|
| SW | CS | ||||||
| Lai | 2018 | 2 | The stable energy level 6 (0.29 mJ/mm2) was kept for 25 min to achieve total 1500 shock | 20 mg triamcinolone acetonite with 2 ml 2% xylocaine were injected into the marker | PFT, VAS, 100-point scoring | NC | 3 |
| Sehriban | 2017 | 3 | A 15-mm head with 2000 shockwave at each session at 10-Hz frequency with an energy flux density per shock of 0.16 mJ/mm2 | Single 1-mL dose of betamethasone sodium plus 0.5 mL of prilocaine | VAS, PFT, HTI, FFI | NC | 6 |
| Mark | 2005 | 3 | 3 applications of 1000 pulses of an energy flux density of 0.08/mm2 | One milliliter betamethasone (5.7 mg) and 2 mL of | VAS, TT scoring | NC | 12 |
| Nayera | 2012 | 2 | Energy intensity applied ranged from 14 to 17 kV, 2 Hz, 1000–1500 pulses, same technique is repeated after two weeks | Injection of 2 mL of 4 mg/mL twice (betamethasone diproprionate and betamethasone sodium phosphate, 0.5% zylocaine hydrochloride) | Mayo CSS | NC | 6 |
| Istemi | 2010 | 1 | A single application of 3,000 shockwaves | A 2-mL syringe filled with 0.5 mL of combined betamethasone | VAS, HTI | Pain ( | 3 |
| Fariba E | 2016 | 5 | 2000 shockwaves/session of 0.2 mJ/mm2, all subjects received 5 sessions of ESWT at 3-day intervals | Injection of 5 ml once a week, 3 times in total | VAS, FFI | NC | 2 |
Fig. 2Risk of bias summary
Fig. 3Forest plot of Mayo CSS, FFI, HFI and 100 Scoring System score in the SW group compared with the CS group from the 3-month follow-up
Fig. 4Forest plot of PFT in the SW group compared with the CS group from the 3-month follow-up
Fig. 5Forest plot of VAS score in the SW group compared with the CS group from the 3-month follow-up